Publications by authors named "E Leinert"
Article Synopsis
- The German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) has established a system for monitoring women at high risk for breast cancer, recommending annual screenings using the BOADICEA risk model for those with a 10-year risk of 5% or more.
- Women with a family history of breast cancer may qualify for increased surveillance as they age, even if their initial risk doesn’t meet the threshold.
- Two methods were compared for determining when a woman's risk increases: the 'prediction by aging pedigree' (AP) which tracks family history over time, and a simpler 'conditional probability' (CP) approach, which estimates future risks based on initial assessments; the CP method was found to be
Article Synopsis
- * The Cardiac Health in Breast Cancer study aims to evaluate how a structured exercise program impacts cardiac health in 48 females undergoing cardiotoxic cancer therapies.
- * Participants will be divided into an intervention group receiving high-intensity training and a control group following general activity guidelines, with a focus on measuring changes in cardiac function and overall well-being over 12 months.
Background: The current standard for the preoperative marking of non-palpable breast lesions is wire guided localization (WGL) which is associated with logistical efforts and patient discomfort. Non-radioactive seeds (NRS) recently challenged the use of WGL; but do they provide a better alternative from a logistical and environmental perspective?
Methods: WGL standard was compared with NRS available in Germany: Magseed®, Pintuition®, SAVI SCOUT ® and LOCalizer™ on a logistical and carbon-footprinting basis. In the logistical analysis the number of patient contacts with the healthcare system for lesion localization/removal and the number of breast punctures were evaluated in two different clinical scenarios (primary surgery and secondary surgery after neoadjuvant treatment).
Introduction: The third-generation antibody-drug conjugates (ADC), trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), recently obtained approval for metastatic breast cancer treatment across various subtypes and therapeutic contexts.
Materials And Methods: This retrospective, multicentric study evaluated real-world tolerability, feasibility and efficacy in a pre-treated, real-world cohort at three major German breast cancer centers.
Results: 125 patients treated with T-DXd or SG from November 2020 to June 2023 were included (T-DXd: 77 patients; SG: 48 patients).
: There are many reports about variations in the menstrual cycle after infection with SARS-CoV-2 or vaccination against it. However, data on SARS-CoV-2 infection or vaccination-related changes in menstruation-associated endometriosis-typical symptoms such as dysmenorrhea, dyspareunia, dyschezia, dysuria, and bloating are rare or missing. : This retrospective study was performed as an online survey among employees and students at the University Hospital Ulm, Germany.
View Article and Find Full Text PDF